Hallek lab

Translational CLL research to develop new standards of clinical care

Our research is focused on identifying new pathways with relevance for the pathogenesis of CLL. To pursue this aim, we employ in vitro biochemical assays, as well as genetically engineered mouse models. We further aim to develop novel, targeted therapies for CLL patients with the aim to achieve a non-toxic, long-term control of this leukemia entity. For that purpose, we perform early phase clinical trials, as well as large approval trials within the German CLL Study Group.

Univ.-Prof. Dr. med. Michael Hallek

CECAD Cologne and Institute for Genetics
Tel.  +49 221 478 4400
michael.hallek[at]uni-koeln.de